Search

Author/Creator Sarnaik, A.

1. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. (December 2022)

Authors:
Hassel, J.C.; Sarnaik, A.; Chesney, J.; Medina, T.; Hamid, O.; Thomas, S.; Wermke, M.; Domingo-Musibay, E.; Kirkwood, J.M.; Larkin, J.; Weber, J.S.; Arance Fernandez, A.M.; Rodriguez, J.F.; Thomas, I.; Corrie, P.G.; Gontcharova, V.; Wu, X.; Shi, W.; Kluger, H.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Essential role of HDAC6 in the regulation of PD‐L1 in melanoma. Issue 5 (6th January 2016)

Authors:
Lienlaf, M.; Perez-Villarroel, P.; Knox, T.; Pabon, M.; Sahakian, E.; Powers, J.; Woan, K.V.; Lee, C.; Cheng, F.; Deng, S.; Smalley, K.S.M.; Montecino, M.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Seto, E.; Weber, J.; Sotomayor, E.M.; Villagra, A.
Journal:
Molecular oncology
Issue:
Volume 10:Issue 5(2016:May)
Page Start:
735
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Issue 7 (24th April 2015)

Authors:
Woan, K.V.; Lienlaf, M.; Perez-Villaroel, P.; Lee, C.; Cheng, F.; Knox, T.; Woods, D.M.; Barrios, K.; Powers, J.; Sahakian, E.; Wang, H.W.; Canales, J.; Marante, D.; Smalley, K.S.M.; Bergman, J.; Seto, E.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Celis, E.
Journal:
Molecular oncology
Issue:
Volume 9:Issue 7(2015:Aug.)
Page Start:
1447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗